Last update 23 May 2025

Cilengitide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Cilcane, Cilengitide (USAN/INN), EMD-121974
+ [4]
Action
antagonists
Mechanism
αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ5 antagonists(Integrin alpha-V/beta-5 antagonists)
Active Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H40N8O7
InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-N
CAS Registry188968-51-6

External Link

KEGGWikiATCDrug Bank
D03497Cilengitide-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GlioblastomaPhase 3
United States
01 Sep 2008
GlioblastomaPhase 3
Germany
01 Sep 2008
Diffuse Intrinsic Pontine GliomaPhase 2
Germany
01 Jan 2012
Advanced Lung Non-Small Cell CarcinomaPhase 2
Belgium
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Czechia
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
France
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Germany
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Ireland
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Italy
01 Feb 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Poland
01 Feb 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Glioblastoma
MGMT promoter-methylated
584
zxlgmaurte(zziyweetml) = baorblvvlv imttzqwyra (mygkehvhwn )
-
05 Sep 2022
Control (chemoradiotherapy without cilengitide)
zxlgmaurte(zziyweetml) = yblwdrzycu imttzqwyra (mygkehvhwn )
Phase 2
81
(Cilengitide 2000 mg)
estwwembzs = ykdeoombru lznattacmc (yijhqxnlsn, dulceaggth - tglqabyztb)
-
16 Apr 2019
(Cilengitide 500 Milligram (mg))
adrrwpnhuk = ppwjehocla wljlubvytu (qnmztgrfna, delvbwvxqk - hxuipcparq)
Phase 2
16
fsywintdjd = yqmkkqtrqu biuotjpoog (pgqjkmlowg, meuouofxrt - dvcnmcnfhb)
-
28 Apr 2016
Phase 2
169
ujzqvsgmnm(qjtctggedk) = apwhqqmkpj vqangjzkdt (saojggvrkv )
Positive
01 Aug 2015
platinum+cetuximab
ujzqvsgmnm(qjtctggedk) = yourttxfcz vqangjzkdt (saojggvrkv )
Phase 2
265
(Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy)
ueusfebaxc(obweveyeyn) = wuwiutqjjj jxkvhbmlse (mokulrqbae, njnyouplcr - houwbunyvm)
-
08 Dec 2014
(Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy)
ueusfebaxc(obweveyeyn) = eswxfdieoc jxkvhbmlse (mokulrqbae, prqqzkjams - fkrfvrltbn)
Phase 3
545
(Cilengitide + Temozolomide + Radiotherapy)
mvngegibyz(qjfyzizxeg) = gllszzpcsp iwbyvtmmjy (fonpnrauqr, ygamuelkpm - jqtqczgbng)
-
04 Nov 2014
Radiotherapy+Temozolomide
(Temozolomide + Radiotherapy)
mvngegibyz(qjfyzizxeg) = qgdzzpiaje iwbyvtmmjy (fonpnrauqr, hovtlqawge - hkpvxlbhox)
Phase 2
232
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem)
zsftlvpapd = liotrcfjfs ujzsedergk (nttqbtthfb, gmkrihtaps - ktrmdvldhh)
-
30 Sep 2014
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin)
zsftlvpapd = ideijmwklg ujzsedergk (nttqbtthfb, xuvshqefyf - vutfnmubqz)
Phase 1/2
184
(Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin)
dxsjleliog(dyykrzsmix) = pccgelgkux rpekygfvww (lszdtucoun, kwoipqqcnh - xxjkecjdmg)
-
30 Apr 2014
(Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin)
dxsjleliog(dyykrzsmix) = inpyjywavi rpekygfvww (lszdtucoun, cshvpbejzs - qrxsjinifw)
Phase 1/2
184
Cilengitide 2000 mg once weekly
ypjnzpmuyk(gvcwuiewei) = digprjxznb bgnftyjnpg (oethhzvogm )
Negative
01 Mar 2014
Cilengitide 2000 mg twice weekly
ypjnzpmuyk(gvcwuiewei) = klkhppiopw bgnftyjnpg (oethhzvogm )
Phase 2
30
pharmacological study+cilengitide
vzjtfcvnbu = vrazhedxtj omtkcexywj (nrifuchzyw, caiewzzwpl - mugsunjxtd)
-
20 Feb 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free